Aclid, founded in 2021, is positioned as a critical player in the Biopharma, Biotechnology, and Life Sciences sectors. Its platform enhances biosecurity and biosafety, ensuring efficient lab operations and compliance in environmental, health, and safety standards. Aclid's solutions are already trusted by leading life sciences companies and government bodies seeking responsible research methodologies.
Headquartered in the United States, Aclid recently secured a $3.30M seed investment led by 2048 Ventures and IA Ventures as of 01 October 2023. This financial boost underscores investor confidence in Aclid's ability to innovate and solve critical issues within the scientific community.
Overall, Aclid represents a promising opportunity for investors seeking to support and scale a company that is not only poised for growth but also essential for advancing safety in biomanufacturing processes.